Lineage Cell Therapeutics (LCTX) EBIAT: 2010-2025
Historic EBIAT for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$29.8 million.
- Lineage Cell Therapeutics' EBIAT fell 881.58% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$67.7 million, marking a year-over-year decrease of 235.95%. This contributed to the annual value of -$18.6 million for FY2024, which is 13.39% up from last year.
- Latest data reveals that Lineage Cell Therapeutics reported EBIAT of -$29.8 million as of Q3 2025, which was up 2.24% from -$30.5 million recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' EBIAT ranged from a high of -$1.4 million in Q1 2021 and a low of -$30.5 million during Q2 2025.
- Over the past 3 years, Lineage Cell Therapeutics' median EBIAT value was -$5.2 million (recorded in 2023), while the average stood at -$9.5 million.
- Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' EBIAT was 83.14% (2021), while the steepest drop was 1,526.77% (2021).
- Quarterly analysis of 5 years shows Lineage Cell Therapeutics' EBIAT stood at -$29.0 million in 2021, then skyrocketed by 78.08% to -$6.4 million in 2022, then rose by 24.85% to -$4.8 million in 2023, then soared by 31.46% to -$3.3 million in 2024, then plummeted by 881.58% to -$29.8 million in 2025.
- Its EBIAT stands at -$29.8 million for Q3 2025, versus -$30.5 million for Q2 2025 and -$4.1 million for Q1 2025.